<div id="readability-page-1"><p>biote Corp. (NASDAQ:BTMD - Get Free Report)'s stock price dropped 0.9% during mid-day trading on Thursday . The company traded as low as $2.18 and last traded at $2.22. Approximately 141,384 shares were traded  during mid-day trading, a decline of 52% from the average daily volume of 296,497 shares. The stock had previously closed at $2.24.</p><h2>Analyst Upgrades and Downgrades</h2><p>BTMD has been the topic of a number of research analyst reports. Weiss Ratings  reissued a &#34;sell (d+)&#34; rating on shares of biote in a research note on Monday, December 29th. Truist Financial reduced their price objective on biote from $5.00 to $4.00 and set a &#34;buy&#34; rating on the stock in a research note on Thursday, April 16th. B. Riley Financial reduced their price objective on biote from $3.00 to $2.00 and set a &#34;neutral&#34; rating on the stock in a research note on Thursday, March 12th. National Bank Financial  set a $2.50 price objective on biote in a research note on Thursday, March 12th. Finally, TD Cowen reduced their price objective on biote from $3.00 to $2.50 and set a &#34;buy&#34; rating on the stock in a research note on Thursday, March 12th. Two investment analysts have rated the stock with a Buy rating, one  has issued  a Hold rating and one  has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $2.75.</p><p><b>View Our Latest Research Report on biote</b></p><h2>biote Stock Performance</h2><p>The firm has a fifty day simple moving average of $1.79 and a 200-day simple moving average of $2.31. The company has a market capitalization of $87.80 million, a PE ratio of 2.96 and a beta of 1.29. </p><p>biote (NASDAQ:BTMD - Get Free Report) last posted its quarterly earnings data on Wednesday, March 11th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.01. biote had a negative return on equity of 23.41% and a net margin of 14.07%.The company had revenue of $46.41 million for the quarter, compared to the consensus estimate of $45.79 million.  As a group, research analysts anticipate that  biote Corp. will post 0.32 EPS for the current fiscal year. </p><h2>Institutional Investors Weigh In On biote</h2><p>Several hedge funds and other institutional investors have recently bought and sold shares of the business. Rothschild Wealth LLC acquired a new position in shares of  biote in the 4th quarter worth approximately $380,000.  Rice Hall James &amp; Associates LLC grew its position in shares of  biote by 86.6% in the 3rd quarter. Rice Hall James &amp; Associates LLC now owns 227,024 shares of the company's stock worth $681,000 after acquiring an additional 105,369 shares in the last quarter.  WINTON GROUP Ltd acquired a new position in shares of  biote in the 3rd quarter worth approximately $309,000.  State Street Corp boosted its position in  biote by 17.3% during the 4th quarter. State Street Corp now owns 600,114 shares of the company's stock valued at $1,560,000 after purchasing an additional 88,402 shares during the period.  Finally, Bridgeway Capital Management LLC boosted its position in  biote by 142.1% during the 2nd quarter. Bridgeway Capital Management LLC now owns 121,053 shares of the company's stock valued at $487,000 after purchasing an additional 71,053 shares during the period. 21.68% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>biote Company Profile</h2> (Get Free Report)<p>biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than biote</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in biote Right Now?</h2><p>Before you consider biote, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and biote wasn't on the list.</p><p>While biote currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

BTMD

<p>biote Corp. (NASDAQ:BTMD) shares fell 0.9% to $2.22 during mid-day trading, with a volume decline of 52% from the average. Analysts have mixed ratings, with Weiss Ratings issuing a 'sell' and Truist Financial a 'buy' with a price target of $4.00. The stock has a consensus rating of 'Hold' and a target price of $2.75. The company reported $46.41 million in revenue and $0.06 EPS for the last quarter, exceeding estimates. Institutional investors hold 21.68% of the stock, reflecting growing interest in the hormone optimization market.</p>

biote (NASDAQ:BTMD) Trading Down 0.9% - What's Next?